Yoshihiro Fukumoto. Show Affiliations »
Abstract
Entities: Disease Gene
Mesh： See more » 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/therapeutic useAnimalsBosentanDrug Therapy, CombinationEpoprostenol/analogs & derivativesEpoprostenol/therapeutic useHumansHypertension, Pulmonary/diagnosisHypertension, Pulmonary/drug therapyHypertension, Pulmonary/geneticsHypertension, Pulmonary/physiopathologyMiceMolecular Targeted TherapyPiperazines/therapeutic useProtein Kinase Inhibitors/pharmacologyProtein Kinase Inhibitors/therapeutic usePurines/therapeutic useRatsSignal Transduction/drug effectsSignal Transduction/geneticsSignal Transduction/physiologySildenafil CitrateSulfonamides/therapeutic useSulfones/therapeutic useVascular Resistance/drug effectsrho-Associated Kinases/antagonists & inhibitorsrho-Associated Kinases/physiology
Substances： See more » PiperazinesProtein Kinase InhibitorsPurinesSulfonamidesSulfonesberaprost1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineSildenafil CitrateEpoprostenolrho-Associated KinasesfasudilBosentan
Year: 2014 PMID： 24717605 DOI： 10.1254/fpj.143.178
Source DB: PubMed Journal: Nihon Yakurigaku Zasshi ISSN： 0015-5691